Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/19—Cytokines; Lymphokines; Interferons
  • A61K38/21—Interferons [IFN]
  • A61K38/215—IFN-beta
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
  • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
  • G01N33/6866—Interferon

Definitions

• This invention relates to factors which modulate inflammation.
• Inflammation occurs in response to tissue injury or infection.
• the acute inflammatory response is marked by fever, increased vascular permeability, alterations in plasma metal and steroid concentrations and leukocytosis.
• Associated with the leukocytosis and localization of the leukocytes to the injured or affected tissue is the release of a barrage of proteolytic enzymes of various specificities which degrade affected tissue and/or invading organisms.
• Control of acute inflammation must be regulated by the body to prevent hyperaccumulation of inflammation-causing agents and thereby avoid degradation of healthy tissue.
• One pathway of control is the stimulation of liver cells, i.e. hepatocytes, to produce a series of plasma proteins known collectively as acute phase proteins.
• the acute phase proteins include antiproteases which inactivate proteolytic enzymes released at the site of injury, clotting and complement components, opsonins and carrier proteins along with others of unknown function.
• the acute phase proteins include ⁇ 1 acid glycoprotein, ⁇ 1 proteinase inhibitor ( ⁇ 1 antitrypsin), ⁇ 1 antichymotrypsin, haptoglobin, hemopexin and fibrinogen in most species along with C-reactive protein, C3 and Factor B complement components and serum amyloid A protein in man and in addition ⁇ 2 macroglobulin and ⁇ 1 cysteine proteinase inhibitor (major acute phase protein) in the rat.
• Some medical conditions are due to an abundance of inflammatory mediators and proteins. Septacemia, or acute pancreatitis, for example, may result in an excess of proteolytic enzymes being released and marked tissue destruction. Conditions such as this may be due to an inadequate release of acute phase proteins to limit inflammation. On the other hand, post-surgery recovery in some patients is associated with infection and poor wound healing which may be due to an inadequate inflammatory response or an excessive anti-inflammatory response. Accordingly, it is possible that once the identity of the liver stimulant is known therapies designed to compensate for its absence or malfunction can remedy such conditions as septacemia and related conditions.
• IL-1 interleukin-1
• TNF tumor necrosis factor
• soluble factors IL-1 and TNF control only a subset of genes encoding the many acute phase proteins in man and rodents, while HSF, of either keratinocyte or peripheral blood monocyte origin, controls the remaining and to some extent all the gene expression of the acute phase proteins.
• the hepatocyte stimulating factor is biochemically, immunologically and functionally identical to the known factor inteferon ⁇ 2 .
• the common identity of these two factors is particularly surprising in that interferon ⁇ 2 has not heretofore been considered to be involved in modulation of the liver and the inflammatory response. Its primary function is thought to be as an anti-viral agent although it is generally recognized that of the known interferons, interferon ⁇ 2 elicits a weak anti-viral effect.
• interferon ⁇ 2 is known to be produced by virus stimulated (poly I:C) fibroblasts.
• the functions and target cells or tissues for interferon ⁇ 2 are described only as either anti-viral or more recently as targeted to the B-lymphocyte cell. None of the activities of interferon ⁇ 2 described in the available literature is related to the liver or to acute phase protein gene regulation.
• the present invention is based on applications of the knowledge herein provided that the hepatocyte stimulating factor is characteristically and biochemically the same substance as interferon ⁇ 2 .
• the present invention comprises, as a new use for interferon ⁇ 2 , the method of stimulating hepatocytes to produce acute phase proteins which comprises treating hepatocytes in vivo with a hepatocyte stimulating amount of interferon ⁇ 2 .
• Treatment may be conducted using, for example, injectable dosage forms for administration either intraparenterally or intravenously.
• a further aspect of the invention comprises a composition of matter comprising interferon ⁇ 2 and a physiologically tolerable carrier.
• such compositions comprise interferon ⁇ 2 in aqueous dosage form, such as buffered saline solutions of interferon ⁇ 2 .
• Ampoules containing powdered interferon ⁇ 2 suitable for aqueous reconstitution as an injectable are also within the scope of the invention.
• the present invention comprises, in other aspects, immunoassays designed to determine the presence or concentration of the hepatocyte stimulating factor, interferon ⁇ 2 , in a fluid sample, such as serum, obtained from the individual that has been injured or infected or whose tissue is suspected of being so affected.
• interferon ⁇ 2 The substance interferon ⁇ 2 is reported to be encoded by the cDNA sequence as reported by Weissenbach et al (1980) PNAS 77, 7152-7156. Substantially the same DNA sequence has been reported to code for a soluble factor known as B-cell stimulating factor (BSF-2) as reported by Hirano et al (1986) Nature 324, 73-76, to code for a 26kD protein and to code for hybridoma plasmacytoma growth factor (HGF).
• BSF-2 B-cell stimulating factor
• HGF hybridoma plasmacytoma growth factor
• interferon ⁇ 2 and glycosylated forms thereof are likely to be produced naturally, being expressed by allelic variations of the DNA sequences reported to date as being interferon ⁇ 2 coding sequences (or BSF-2 or 26kD protein coding sequences).
• these polymorphic forms of interferon ⁇ 2 have a polypeptide component which shares the biological function known presently for interferon ⁇ 2 and, importantly, shares the herein described function of stimulating hepatocytes to produce acute phase proteins, such polymorphic forms of interferon ⁇ 2 are useful in the present invention and are encompassed herein by the term "compounds having substantially the same biological function and biochemical identity as interferon ⁇ 2 ".
• Interferon ⁇ 2 may be prepared, for example, by extracting the compound from lipopolysaccharide-induced monocytes or from poly I:C-induced fibroblasts, but the processes for producing recombinant interferon ⁇ 2 are able to produce greater quantities more conveniently and are therefore preferred.
• One method for producing recombinant interferon ⁇ 2 is described by Hirano et al in Nature, Volume 324, Nov. 6, 1986, incorporated herein by reference.
• the recombinant interferon ⁇ 2 produced by this method will have an apparent molecular weight between 23 and 30 kD, an isoelectric point around 5.0 and will have the partial amino acid sequence described by Hirano et al, supra.
• the method of the present invention in which hepatocytes are stimulated to produce acute phase proteins, can be conducted by treating the hepatocytes with interferon ⁇ 2 admixed with any suitable carrier.
• Parenteral or intravenous administration is preferred in order to introduce the interferon ⁇ 2 to the hepatocytes.
• injectable solutions of interferon ⁇ 2 are preferred herein and may be formulated using protocols well established by the pharmaceutical industry.
• compositions comprising interferon ⁇ 2 and a physiologically tolerable vehicle, such as saline or phosphate buffered saline, optionally in combination with a solubilizing agent for the active ingredient, such as mannitol, are suitable for administration.
• Hepatocyte stimulating amounts of interferon ⁇ 2 will be in the range from about 1 to about 500 ⁇ g/kg body weight of the individual to be treated. Accordingly, compositions suitable for use in the method of the present invention will comprise interferon ⁇ 2 in an amount which reflects this range. Unit doses may be formulated for single injection of required interferon ⁇ 2 , perhaps more appropriately, for repeated injection or by intravenous ⁇ drip ⁇ to attain desired in vivo levels of interferon ⁇ 2 and thereby reduce the risk of toxic side effects. It should be noted that physiologically tolerable carriers should be selected to exclude those carriers which are apt to cause inflammation even to a minor extent.
• interferon ⁇ 2 to stimulate hepatocyte production of acute phase proteins could either compensate for the body's inability to produce interferon ⁇ 2 in response to tissue injury or invasion or could augment the acute phase protein response in cases where sufficient functional interferon ⁇ 2 is not naturally produced.
• a diagnostic assay designed to detect the presence or concentration of an anti-interferon ⁇ 2 -binding substance in a fluid sample extracted from a patient.
• an assay does not differ significantly from standard immunoassays described in the art for assaying other biological substances representative of other conditions or diseases e.g. assaying for HCG to diagnose pregnancy, etc.
• Antibody against interferon ⁇ 2 may be raised in rabbits, goats, sheep etc., recovered and then used to detect the presence of or to determine the concentration of its binding partner, interferon ⁇ 2 .
• antibody to interferon ⁇ 2 is immobilized e.g.
• Bound interferon ⁇ 2 may be detected using any one of several techniques available in the art but preferably using a labelled sandwiching antibody for the captured interferon ⁇ 2 and then detecting the label bound in the assay. It is likely that background levels of interferon ⁇ 2 will persist in healthy individuals. Accordingly, diagnosis of conditions caused by inadequate serum levels of functional interferon ⁇ 2 will require an appraisal of the relative availability of interferon ⁇ 2 in a patient's serum with the interferon ⁇ 2 serum level found in healthy individuals.
• the reference serum level of interferon ⁇ 2 can easily be determined by assaying a representative number of serum samples from a control population. Clearly, those individuals with visible tissue injury/inflammation testing negative for interferon ⁇ 2 levels in the serum assay are candidates for interferon ⁇ 2 administration.
• the assay described herein may also be used to detect tissue injury. Acute phase proteins will normally appear in serum about 24 hours after injury. Accordingly, the presence of interferon ⁇ 2 in serum, which stimulates liver to produce the acute phase proteins, should be present in the serum, and may therefore be assayed, within 24 hours from injury. Such an assay is similar in purpose to known assays which determine the presence or concentration of acute phase proteins in the serum. However, because the assay for IFNB 2 is designed to detect the agent responsible for liver stimulation rather than the result of that stimulation, the IFNB 2 assay can be used to detect tissue injury much earlier than is possible with known methods. This is especially important in situations where tissue injury is internal, i.e. cannot be diagnosed by observation. By providing a rapid assay for IFNB 2 , physicians are provided with a means for assessing internal injury prior to acute phase protein production and without surgical exploration.
• hepatocyte stimulating factor As defined by established criteria, human peripheral blood monocyte conditioned medium was prepared as previously described by Koj et al in Immunology (1987) 60, 203-207. In brief, monocytes, separated by buoyant density centrifugation and further purified by adherence, were stimulated with 10 ⁇ g/ml lipopolysaccharide (E. coli 055:85, TCA extracted, Sigma, St. Louis) for 24 h at 37° C. The supernatant was dialysed (Spectropore 6-8000) against phosphate buffered saline and filter-sterilized.
• 10 ⁇ g/ml lipopolysaccharide E. coli 055:85, TCA extracted, Sigma, St. Louis
• human fibroblast conditioned medium (Fib-CM) was obtained from primary human lung fibroblast lines which have been established from normal lung explants (see Jordana et al, J. Leukocyte Biol., in press).
• PDGF platelet-derived growth factor
• HepG2 human hepatoma cells
• DMEM Dulbecco's Modified Eagle Medium
• FCS heat-inactivated FCS
• Hepatocyte stimulation activity and induction of acute phase protein synthesis was carried out as described by Baumann (1987) supra for HepG2 cells and as described by Koj et. al. (1985) supra for rat hepatocytes.
• a unit of HSF activity is that concentration required to induce one-third of the maximal stimulation of ⁇ 1 antichymotrypsin, serving as a representative acute phase protein, in HepG2 cells and one half of the maximal stimulation of ⁇ -2 macroglobulin in rat hepatocytes.
• the assays have previously been shown to be reproducible having an assay coefficient of variation, CV, of 4% and between assay CV of 10%. In each case, the cells were exposed to soluble factor-containing medium for various times by repeated addition in fresh media.
• the amounts of acute phase proteins secreted into the medium during a set period of time during the final period of exposure in culture was determined by rocket immunoelectrophoresis using monospecific antisera for the various proteins, as described by Koj et. al. (1984) Biochem J. 224, 505-514 and by Baumann et. al. J. Biol. Chem. 258, 563-570.
• the assay for lymphocyte activating factor activity of interleukin-1 (IL-1) preparations was carried out using the PHA co-stimulator assay and C3H/HaJ thymocytes as described by Koj et. al. 1984, supra.
• Antibody preparations and neutralizations used herein include: rabbit anti-human recombinant tumor necrosis factor; rabbit anti-human recombinant interleukin-1 ⁇ ; rabbit anti-human recombinant 1 ⁇ ; rabbit anti-interferon ⁇ , (one ml neutralizes 1,000 units of 1FN ⁇ 2 activity); sheep anti-IFN ⁇ (N.I.H. research reference reagent, cat. no. G-028-501-568) and control sheep antiserum; calf anti-IFN ⁇ 1 and ⁇ 2 and monoclonal anti-human IFN ⁇ (Boehringer Mannheim, cat. no. 853577).
• Absorptions with the various antisera were carried out by incubating a standard pool sample of PBM-CM with increasing amounts of each antibody and control serum. The supernatant was incubated 1 h, 37° C., filter sterilized and tested in the hepatocyte assay and LAF assay for residual activity.
• Recombinant cytokines were also used, including recombinant purified human TNF (5 ⁇ 10 7 U/mg); recombinant purified human IL-1 ⁇ (6 ⁇ 10 8 units/mg) and IL-1 ⁇ (2 ⁇ 10 8 U/mg) and recombinant purified human BSF-2 (IFN ⁇ 2 ) (2 ⁇ 10 5 U/ml).
• hepatocyte stimulating factor To examine the identity of the hepatocyte stimulating factor, the effect of preincubation with various antibody preparations on the HSF activity of perepheral blood monocyte cultured medium, which contains a complex mixture of these various activities.
• preincubation with various antibody preparations Using a standard stimulus of PBM-CM, preabsorption with anti-IL-1 ⁇ and anti-IL-1 ⁇ removed all of the lymphocyte activating factor (LAF) activity, 80% of the ⁇ 1 acid glycoprotein induction and 20-25% of the albumin reduction. Similar trends are observed following absorption of PBM-CM with anti-TNF. Since these antibodies are polyclonal and raised against recombinant material, lack of reactivity with HSF would rule out a serologic relationship between these cytokines.
• LAF lymphocyte activating factor
• the same supernatant did not exhibit any IL-1 activity in an LAF assay.
• the amount of HSF activity in fibroblast CM was approximately equal, on a per cell basis, to that found in PBM-CM.
• LPS-activated monocytes released a hepatocyte stimulating factor which stimulates the production of all of the antiproteinases (cysteine proteinase inhibitor, ⁇ 2 macroglobulin, contrapsin, ⁇ 1 antitrypsin), hemopexin and fibrinogen in a major way, while having a lesser but significant stimulating effect on the synthesis of ⁇ 1 acid glycoprotein, haptoglobin and C3.
• this activity represents a full spectrum HSF.
• HSF and IL-1 ⁇ along with permissive levels of glucocorticoid are likely to represent the full content of hepatocyte specific activities in PBM conditioned medium.
• fibroblasts release a molecule causing identical stimulation of hepatocytes as does monocyte HSF (Table 1) and were able to totally absorb out this activity with the same anti-IFN ⁇ 2 that neutralized HSF. This neutralization could remove all hepatocyte stimulating activity when the fibroblast conditioned media contained no IL-1 or TNF.
• monocyte HSF is serologically related to fibroblast HSF and in turn to fibroblast IFN ⁇ 2 .

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Molecular Biology (AREA)
• Chemical & Material Sciences (AREA)
• Biomedical Technology (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Cell Biology (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Pathology (AREA)
• General Physics & Mathematics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Analytical Chemistry (AREA)
• Microbiology (AREA)
• Physics & Mathematics (AREA)
• Food Science & Technology (AREA)
• Pharmacology & Pharmacy (AREA)
• Physiology (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Gastroenterology & Hepatology (AREA)
• Zoology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (5)

Applications Claiming Priority (1)

Publications (1)

Family

ID=22128118

Family Applications (1)

Country Status (5)

Cited By (6)

Families Citing this family (7)

Citations (6)

Family Cites Families (1)

• 1987
  • 1987-07-20 US US07/075,809 patent/US4973478A/en not_active Expired - Fee Related
• 1988
  • 1988-07-20 AT AT88306654T patent/ATE114973T1/de not_active IP Right Cessation
  • 1988-07-20 JP JP63179314A patent/JPH01110633A/ja active Pending
  • 1988-07-20 DE DE3852377T patent/DE3852377D1/de not_active Expired - Lifetime
  • 1988-07-20 EP EP88306654A patent/EP0317050B1/de not_active Expired - Lifetime

Patent Citations (6)

Non-Patent Citations (15)

Also Published As

Similar Documents

Legal Events